Celiac disease is an autoimmune disorder triggered by gluten ingestion in genetically susceptible individuals, causing immune-mediated damage to the small intestine.
Over 25 companies are developing 30+ therapies for celiac disease, with recent positive trial results and FDA Fast Track designation. A new blood test using T-cell receptor sequencing may enable noninvasive diagnosis and monitoring.
Teva and Sanofi reported durable 44-week efficacy for duvakitug in inflammatory bowel disease, while the FDA accepted Teva's application for TEV-749, a once-monthly olanzapine injection for schizophrenia.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07585669 |
Effects of Omega-3 Fatty Acids on Inflammation and Gut Microbiota in Celiac Disease |
RECRUITING | NA |
| NCT07584473 |
NCWS or IBS/FD in Relatives of CD Patients |
RECRUITING | NA |
| NCT07556328 |
Histomolecular Profiling in Small-Bowel Diseases |
RECRUITING | |
| NCT07515105 |
Gluten Free Oat (Cultivar Saul) in Celiac Disease in Remission |
COMPLETED | NA |
| NCT07453589 |
Small Bowel Ultrasound and Antibody Levels in Celiac Disease Activity |
NOT_YET_RECRUITING | |
| NCT07387185 |
AI System for Detection and Characterization of Chronic Enteropathies |
RECRUITING | |
| NCT07377565 |
A First-in-Patient Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease |
RECRUITING | PHASE1 |
| NCT07366151 |
Long-term Health Outcomes of Screen Detected and Potential Celiac Disease Patients |
NOT_YET_RECRUITING | |
| NCT07362654 |
Single-cell Immune Response to Controlled Gluten Ingestion in Pediatric Celiac Disease |
RECRUITING | NA |
| NCT07298343 |
Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease |
RECRUITING | PHASE2 |
